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Introduction {#sec1}
============

Pulmonary neuroendocrine cells (PNECs) are endogenous chemosensory cells that form around gestational week 8 in humans, making them the first differentiated cell type to appear in fetal lung ([@bib8]). Innervated clusters of PNECs in the human airway epithelium are referred to as "neuro-epithelial bodies or NEBs" ([@bib26], [@bib27]). PNECs are multifunctional cells with known roles in oxygen sensing, redistribution and regulation of blood flow especially during hypoxia, modulation of immune responses, and stimulation of intraepithelial vagosensory nerve fibers ([@bib30], [@bib49]). In addition, PNECs have been reported to serve as a stem cell niche during severe lung injury, with the potential to give rise to club and ciliated cells ([@bib38], [@bib47]). PNEC ontogeny, however, is not entirely clear. A recent lineage tracing study in mice showed that a small population of cells expressing the basal cell marker, tumor protein 63^+^ (TP63^+^), and labeled at embryonic day (E) 9.5, gave rise to calcitonin gene-related polypeptide alpha (CGRP)-expressing PNECs, that can be detected at E18.5 by immunostaining ([@bib60]). However, whether basal cells have the capacity to give rise to PNECs in the human fetal or adult lung remains to be determined.

A spectrum of lung disorders including neuroendocrine hyperplasia of infancy (NEHI), chronic obstructive pulmonary disease (COPD), cystic fibrosis, asthma, bronchopulmonary dysplasia (BPD), and pulmonary hypertension are associated with expansion of PNECs in the airway epithelium ([@bib7], [@bib11], [@bib18], [@bib22], [@bib21], [@bib39], [@bib43]). The pathophysiological consequences of increased PNEC abundance in these diseases is not clear. As PNECs comprise \<1% of all respiratory cell types, primary PNECs are inherently difficult to isolate in sufficient quantities for detailed characterization. We, therefore, addressed an unmet need to develop a model system for efficiently generating human PNECs to study their physiological and pathological functions using induced pluripotent stem cells (iPSCs).

Within the lung milieu, activation of pro-neural transcription factor *ASCL1* (Achaete-Scute Family BHLH Transcription Factor 1) is required for cells to form the pulmonary neuroendocrine lineage ([@bib30]). The Notch-HES1/HEY1 (Hairy/Enhancer-Of-Split related BHLH transcription factor family) pathway regulates the non-neuroendocrine fate of lung endoderm by repressing pro-neural genes like *ASCL1* ([@bib19], [@bib35]). Recently, it has been shown that inhibition of Notch can increase PNEC production ([@bib6]). These studies, however, focused specifically on modeling small cell lung carcinoma (SCLC) using human embryonic stem cell-derived PNECs, or on generating proximal airway epithelial spheroids from human pluripotent cells ([@bib6], [@bib25]). In-depth characterization of iPNECs or comparison at the transcriptional level with primary PNECs was not performed. In this article, we report the differentiation of iPSCs to human iPNECs with a gene expression profile similar to that of primary fetal PNECs that could be used in future studies of pathophysiological changes in diseases such as NEHI or BPD.

Results {#sec2}
=======

Directed Differentiation of iPSCs to iPNECs {#sec2.1}
-------------------------------------------

We adapted our previously published differentiation protocol to create airway epithelium from human iPSCs, recapitulating the key stages of embryonic lung development ([@bib13]). iPSCs were differentiated in culture without sorting, resulting in a mixed population of mesoderm and epithelium comprising the proximal airways. To validate the presence of PNECs in our directed differentiation, cultures were stained for a panel of genes known to be expressed in primary human PNECs ([@bib30], [@bib49]), including synaptophysin (SYP), chromogranin A (CHGA), PGP9.5 (expressed by the gene *UCHL1*), and neuron-specific enolase (ENO2). After 31 days of differentiation, including culture at an air-liquid interface (ALI) from Day 17, cells expressing these PNEC markers were observed in cultures generated from three independent iPSC lines ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A). Expression of SYP, CHGA, PGP9.5, and ENO2 was quantified as a percentage of the mean fluorescence intensity (MFI) of the respective marker normalized to the expression of nuclear marker 4′,6-diamidino-2-phenylindole (DAPI). The distribution of these markers ranged from 31.64% ± 3.01% MFI for SYP to 61.20% ± 4.78% MFI for ENO2 ([Figure 1](#fig1){ref-type="fig"}B). Orthogonal projection of the differentiated cultures revealed that iPNECs are present in closer proximity to the apical-air interface ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Analysis of key PNEC markers, including ENO2 and SYP, throughout the differentiation time course from iPSC indicated that ENO2 protein was robustly expressed from Day 13 ([Figure S2](#mmc1){ref-type="supplementary-material"}A), whereas SYP expression was increased gradually after exposure at the ALI, from Day 17 onward. ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Expression of these PNEC markers was additionally validated in explanted human adult lung tissue sections ([Figure 1](#fig1){ref-type="fig"}C). Cells expressing SYP, CHGA, and PGP9.5 were identified within the epithelium of the distal airways. In support of observations in our iPNEC cultures, ENO2 expression was also more widespread than the other PNEC markers in the human lung sections ([Figure 1](#fig1){ref-type="fig"}C), consistent with ENO2 being expressed in other lung cells in addition to PNECs. Indeed, our data indicated that KRT5^+^ basal cells co-express ENO2 in adult human lung tissues ([Figure S2](#mmc1){ref-type="supplementary-material"}C). This is also supported by data deposited in the LungMAP database ([www.lungmap.net](http://www.lungmap.net){#intref0010}). Gastrin-releasing protein (GRP), also known as bombesin, is another key marker of PNECs whose expression peaks during human fetal lung development around week 20--23 ([@bib30], [@bib49], [@bib50]). GRP mRNA expression peaked during specification of the primordial lung progenitor cells from ventralized anterior foregut endoderm, Days 13--17 of our iPSC differentiation protocol ([Figure S2](#mmc1){ref-type="supplementary-material"}D), and then decreased.Figure 1Directed Differentiation of Human iPSCs into iPNECs(A) Representative immunofluorescence (IF) images of iPNECs at Day 31 of differentiation at the ALI show expression of SYP, CHGA, PGP9.5, and ENO2 (all red). Left panels (20×) represent low-power images (scale bars, 50 μm), and right panels (40×) show magnified views (scale bars, 10 μm).(B) Quantification of PNEC marker expression at Day 31 of differentiation expressed as percentage MFI of each marker in relation to total DAPI fluorescence. Data are expressed as mean ± SEM from 3 independent experiments.(C) Representative IF images of primary PNECs in adult human distal lung show expression of SYP, CHGA, PGP9.5, and ENO2 (all red). Yellow dotted lines demarcate the airways. Left panels (20×) represent low-power images (scale bars, 100 μm), and right panels (40×) show magnified views of the marked areas (scale bars, 50 μm).(D) Representative IF images of iPNECs in submerged and ALI cultures stained for SYP (green). Scale bars, 200 μm. Nuclei are counterstained with DAPI (blue).See also, [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Induction of PNECs Is Augmented by Air-Liquid Interface Culture during Directed Differentiation {#sec2.2}
-----------------------------------------------------------------------------------------------

Based on our observations that SYP expression increased after exposure of the differentiation cultures to an ALI, we evaluated whether the air interface was an important factor in PNEC induction. We continued the culture of primordial lung progenitors at Day 17 of differentiation ([@bib13]), in both submerged and ALI conditions. Owing to consistency in staining across experimental replicates, the relative MFI of SYP:DAPI was compared ([Figure 1](#fig1){ref-type="fig"}B). After 14 additional days of differentiation through to experimental Day 31, SYP^+^ iPNECs were only detected in the presence of an ALI ([Figure 1](#fig1){ref-type="fig"}D, bottom panel). No SYP-expressing cells were observed in continually submerged cultures ([Figure 1](#fig1){ref-type="fig"}D, top panel), indicating that air exposure provides a microenvironment suited to the continued development of PNECs.

Characterization of Human iPNECs {#sec2.3}
--------------------------------

To comprehensively characterize and validate iPNECs, we co-labeled the differentiating cultures with NKX2.1, a primordial lung endoderm transcription factor; EPCAM, a pan-epithelial marker; and vimentin, VIM, a mesenchymal marker, in combination with the PNEC marker SYP. SYP^+^ iPNECs co-express NKX2.1 supporting a lung endodermal origin, but do not express VIM or EPCAM ([Figures 2](#fig2){ref-type="fig"}A and 2B). Human lung tissue sections were used to validate this co-staining pattern: primary PNECs within these sections also co-express NKX2.1, but not EPCAM or VIM, supporting our iPNEC data ([Figure 2](#fig2){ref-type="fig"}B). NKX2.1 also identifies neuronal cells developing in the forebrain ([@bib15], [@bib17]); therefore, to exclude the possibility that our differentiation was creating forebrain neurons we stained for additional neuronal-specific marker, microtubule-associated protein 2 (MAP2), at Days 31 and 60 of differentiation. No MAP2 expression was evident at either of these time points (data not shown).Figure 2Characterization of Human iPNECs(A) Representative immunofluorescence (IF) images of ALI cultures at Day 31 of directed differentiation: SYP^+^ iPNECs (red), NKX2.1, EPCAM, and vimentin (VIM) (all green). Left panels (20×) represent low-power images (scale bars, 200 μm), and right panels (40×) show magnified views of the marked areas (scale bars, 10 μm).(B) Representative IF images of adult human distal lung sections: SYP^+^ iPNECs (green), NKX2.1, EPCAM, and VIM (all red). Yellow dotted lines demarcate the airways. Left panels (20X) represent low-power images, and right panels (40×) show magnified views of the marked areas (scale bars, 50 μm). Nuclei are counterstained with DAPI (blue).

NOTCH Inhibition Augments iPNEC Specification and Phenotypic Complexity {#sec2.4}
-----------------------------------------------------------------------

A transcriptional program regulated by transcription factor *ASCL1* is required for activating the neuroendocrine lineage in developing lung to generate PNECs ([@bib30]). ASCL1 expression is known to be repressed by NOTCH signaling, which supports expansion and differentiation of lung basal and secretory cells, respectively. During iPSC differentiation, *ASCL1* mRNA is detectable from Day 10 ([Figure S2](#mmc1){ref-type="supplementary-material"}E), preceding the appearance of SYP^+^ cells from Day 13 ([Figure S2](#mmc1){ref-type="supplementary-material"}B). We also observe that expression of *HEY1/HES1*, downstream targets of the NOTCH pathway, peaks between Days 10 and 17 of differentiation ([Figures S2](#mmc1){ref-type="supplementary-material"}F and S2G), whereas *ASCL1* peaks at Day 31 ([Figure S2](#mmc1){ref-type="supplementary-material"}E). This suggests that in our differentiation protocol, much like during development, there is an inverse correlation between activity of the Notch signaling pathway and ASCL1 expression. To evaluate the impact of Notch inhibition on neuroendocrine differentiation and expansion during our differentiation protocol, we performed a dose-response to γ-secretase/Notch inhibitor, 3tert-Butyl(2S)-2-\[\[(2S)-2-\[\[2-(3,5-difluorophenyl) acetyl\] amino\] propanoyl\] amino\]-2-phenylacetate (DAPT). As before, marker expression was quantified as a percentage of the MFI for the respective marker normalized to the MFI of nuclear marker DAPI. Continuous addition of 1, 10, and 20 μM DAPT to cultures from Day 17 onward resulted in a dose-dependent increase in the relative MFI of SYP at Day 31 ([Figures S3](#mmc1){ref-type="supplementary-material"}A, [3](#fig3){ref-type="fig"}A, and 3B). The effect of Notch inhibition was validated using a second Notch signaling inhibitor, dibenzazepine (DBZ), at 0.5, 2, and 5 μM. A 2-fold increase in relative MFI of SYP was observed when increasing the concentration of DBZ from 0.5 to 2 μM ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}B). However, no further increase in the MFI ratio of SYP was observed with an increase to 5 μM DBZ treatment. These findings support inhibition of Notch signaling as an important mechanism for augmenting PNEC differentiation and expansion. To deduce the optimal concentrations of Notch inhibitors, DAPT and DBZ, required for iPNEC differentiation, we also co-labeled Day 31 cultures with cleaved caspase 3, an apoptotic marker to evaluate whether high concentrations of Notch inhibitors induced toxicity and cell death. Based on immunofluorescent staining, an increase in the caspase 3^+^ relative MFI percentage was observed at the highest concentration (20 μM DAPT and 5 μM DBZ) of the Notch inhibitors ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B), indicating that 10 μM DAPT or 2 μM DBZ were optimal for induction of iPNECs. These concentrations were used for all subsequent experiments. Extended culture of iPNECs with continuous addition of DAPT/DBZ for up to 90 days resulted in a significant increase in mRNA expression for representative PNEC genes *ASCL1, DLL3, GAD1/GAD67, ENO2, ROBO2,* and *SYP* ([Figure 3](#fig3){ref-type="fig"}D). In addition, there was a significant increase in SYP, ROBO2, and CHGA staining ([Figures 3](#fig3){ref-type="fig"}E, 3F, and 3H). ENO2 was robustly expressed by Day 31 with no further increase at Day 91 ([Figure 3](#fig3){ref-type="fig"}G). These data support a role for continuous repression of Notch signaling in augmenting iPNEC expansion and homeostasis. Interestingly, SYP, ROBO2, and ENO2 staining patterns show an intricate arborized network formation over time in culture. Using Sholl analysis ([Figure S4](#mmc1){ref-type="supplementary-material"}A), we quantified this arborization as a change in the number of intersections ([Figures S4](#mmc1){ref-type="supplementary-material"}B, S4D, and S4F) and branching density ([Figures S4](#mmc1){ref-type="supplementary-material"}C, S4E, and S4G) of SYP^+^, ROBO2^+^, and ENO2^+^ iPNECs ([@bib2], [@bib3], [@bib46], [@bib48], [@bib64]). Such changes in the cellular complexity of the iPNECs likely reflect phenotypic maturation similar to that observed in the NEBs of adult lungs ([@bib40], [@bib39]).Figure 3Extended Notch Inhibition Increases iPNEC Specification and Phenotypic Complexity(A--C) (A) Representative immunofluorescence (IF) images and quantification of SYP^+^ iPNECs (red) at Day 31 of differentiation in the presence of DAPT (1 μM and 10 μM). Quantification of SYP expression (MFI expressed as a percentage of total DAPI fluorescence) at Day 31 of differentiation in the presence of (B) DAPT (1 μM and 10 μM) (paired t test) and (C) DBZ (0.5 μM, 2 μM and 5 μM) (one-way ANOVA). Data are expressed as mean ± SEM from 3 independent experiments. ∗∗p \< 0.01, ∗∗∗∗p \< 0.0001.(D--L) (D) Quantitative RT-PCR showing PNEC marker expression after 91 days of differentiation. Data are normalized to internal control β-actin and expressed as comparisons among Days 31, 60, and 91 with respect to Day 0. N = 3 experimental replicates each with 3 technical replicates. One-way ANOVA. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗∗p \< 0.0001. MFI expressed as percentage of DAPI fluorescence for cells expressing SYP^+^ (E), ROBO2^+^ (F), ENO2^+^ (G), and CHGA^+^ (H) at Days 31, 60, and 91 of differentiation. One-way ANOVA. ∗∗p \< 0.01, ∗∗∗∗p \< 0.0001. Scale bars, 100 μm. Nuclei are counterstained with DAPI (blue). (E) Representative IF images show SYP^+^ (I), ROBO2^+^ (J), ENO2^+^ (K), and CHGA^+^ (L) cells at Days 31, 60, and 91 of differentiation (all red).See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

Transcriptomic Characterization of iPNECs {#sec2.5}
-----------------------------------------

To evaluate the transcriptomic profile of iPNECs, we performed single-cell RNA sequencing (scRNA-seq) of cultures maintained with continuous treatment with 10 μM DAPT at Day 91 of iPSC differentiation (for schematic see [Figure S5](#mmc1){ref-type="supplementary-material"}A). Two independent biological replicates were sequenced and analyzed. Based on the quality parameters as detailed in [Transparent Methods](#mmc1){ref-type="supplementary-material"}, we selected a set of 1,705 and 1,502 cells from replicates 1 and 2, respectively, for analysis. The two replicates were corrected for any batch effect before further analysis. A subset of 1,171 most variable genes that showed a high level of concordance between the two replicates was selected for further downstream analysis (Pearson correlation coefficient, r = 0.94, [Figure S5](#mmc1){ref-type="supplementary-material"}B). A flowchart describing the bioinformatics analysis pipeline for the scRNA-seq data is shown in [Figure S5](#mmc1){ref-type="supplementary-material"}C. Unsupervised graph-based clustering (false discovery rate, FDR p \< 0.05) and non-linear dimensionality reduction distributes the cells into six independent cell populations on Day 91 of differentiation ([Figure 4](#fig4){ref-type="fig"}A). Two of these clusters, labeled iPNEC^1^ and iPNEC^2^, representing \>30% of the cells captured, were defined by a transcriptomic signature to reflect a neuroendocrine lineage determined by the expression of known PNEC genes including, but not limited to, *SYP, CHGA, PGP9.5, ENO2,* and *ROBO2*. Further in-depth analysis revealed that these two clusters are separated from the other cell clusters by differential expression (fold change, FC) of key PNEC marker genes *SYP, ENO2, UCHL1,* and *CHGA,* and Notch pathway genes, *HES1* and *NOTCH2* ([Figure 4](#fig4){ref-type="fig"}B). The larger cluster, iPNEC^1^ (yellow dots), has a higher degree of Notch repression and a higher FC of *SYP, ENO2, UCHL1,* and *CHGA* than the smaller cluster, iPNEC^2^ (blue dots). For all subsequent analyses the two clusters, iPNEC^1^ and iPNEC^2^ were grouped together as iPNECs. A set of 255 differentially enriched genes (FDR p \< 0.05; FC ≥ 1.5) was identified using gene set enrichment analysis against a compendium of 350 different human tissues and cell types; we refer to this set of genes as iPNEC-associated genes. [Figure S5](#mmc1){ref-type="supplementary-material"}C shows a flowchart describing the process of identifying 255 iPNEC-associated genes. In a genome-wide comparison, these 255 genes are significantly enriched (FDR p \< 0.5, FC ≥ 1.5) in the putative iPNEC cell population compared with other populations ([Figure 4](#fig4){ref-type="fig"}C) and includes established PNEC marker genes including *SYP, CHGA,* and *ROBO2* ([Figure 4](#fig4){ref-type="fig"}D). *UCHL1*, although highly enriched within the iPNEC cluster, is also expressed in the non-iPNEC population. According to the LungMAP database, *UCHL1* is also expressed to some extent by lung mesenchyme ([www.lungmap.net](http://www.lungmap.net){#intref0015}). We observed co-differentiation of mesenchymal-like clusters in our Day 91 cultures (VIM^+^ fibroblast-like and ACTA2^+^ smooth muscle cells in [Figure 4](#fig4){ref-type="fig"}A), which could contribute to *UCHL1* expression within the non-iPNEC population. PNECs receive stimulation from neurotransmitters/neurosecretions innervating the lung and respond to such stimuli by releasing hormones (neuropeptides and amines). PNECs, therefore, have important functions in assimilating characteristics of both the nervous and endocrine systems. Accordingly, analysis of the pathways most enriched in the 255 gene set includes neuronal system development, synaptic vesicle biogenesis, and bioactive peptide signaling ([Figure 4](#fig4){ref-type="fig"}E), consistent with some of the known functions of PNECs. We also observe Notch signaling as one of the most differentially altered pathways ([Figure 4](#fig4){ref-type="fig"}G), reflecting the fact that continued Notch inhibition was administered to induce a neuroendocrine fate.Figure 4Transcriptomic Characterization of iPNECs(A) tSNE plot identifies six cell clusters in two replicates of 91-day old iPSC differentiated cells.(B) Expression of representative genes between iPNECs^1^ and iPNECs^2^. Fold change represents differential expression between iPNEC^1/2^ clusters versus other cells.(C) Box whisker plot comparing 255 iPNEC-associated genes within iPNEC and non-iPNEC populations. Key PNEC markers are shown (CHGA, SYP, UCHL1, ENO2, and NEUROD1).(D) Violin plots showing expression of individual PNEC marker genes (ROBO2, CHGA, SYP, and UCHL1) within iPNEC and non-iPNEC populations.(E) Signaling pathways altered within 255 iPNEC-associated genes.(F) Scatterplot showing concordance of expression of 151 common genes (Pearson correlation coefficient, r = 0.75) in Day 91 iPNECs and human fetal lung-derived primary PNECs pooled from gestational weeks 15, 18, and 21.(G) Heatmap comparing the gene expression signature between iPNECs and human fetal lung-derived primary PNECs pooled from gestational weeks 15, 18, and 21.(H) Venn diagram showing the number of genes overlapping between iPNECs and human fetal lung-derived primary PNECs and the known key PNEC markers that are common between the two samples.See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.

Given the limited number of PNECs in human lung, performing RNA sequencing on primary PNECs is challenging. We, therefore, procured the only available scRNA-seq dataset of human fetal lung explants pooled from gestational weeks 15, 18, and 21 (EMBL-EBI ArrayExpress Database: [E-MTAB-8221](array-express:E-MTAB-8221){#interref55}) ([@bib32]) and compared the neuroendocrine cluster (220 cells) with the iPNEC cluster within our scRNA-seq dataset (GEO accession number: [GSE146990](ncbi-geo:GSE146990){#intref0020}). Comparative analysis revealed a significant correlation coefficient (r = 0.75) with a high concordance of 151 genes found to be commonly expressed between iPNECs and fetal PNECs ([Figure 4](#fig4){ref-type="fig"}F). One-way hierarchical clustering indicates an overall similar gene expression pattern between iPNECs and human primary fetal PNECs ([Figure 4](#fig4){ref-type="fig"}G) including expression of all known major PNEC genes such as *SYP, CHGA, PGP9.5, ROBO2, ASCL1, NCAM1, ENO2, DLL3,* and *NEUROD1* ([Figure 4](#fig4){ref-type="fig"}H and [Tables S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, and [S3](#mmc4){ref-type="supplementary-material"}), indicating considerable overlap between the transcriptomes of iPNECs and primary human fetal PNECs.

PNECs are considered neuroepithelial in nature; however, we did not observe co-staining of iPNECs or primary PNECs in human lung tissue sections stained with epithelial marker EPCAM ([Figures 2](#fig2){ref-type="fig"}A and 2B). To further clarify the whether EPCAM is expressed in PNEC we further analyzed the scRNA-seq data. In fetal PNECs, Miller et al., identified a neuroendocrine cell population within a computationally extracted epithelial cluster based on high EPCAM expression ([@bib32]). Detailed analysis of the human fetal lung scRNA-seq data enabled a differentiation of two subsets of fetal PNECs based on EPCAM expression: of the 220 fetal PNECs 77 were EPCAM^+^ and 143 EPCAM^−^. Analysis of our 255 PNEC-associated genes in EPCAM^−^ fetal PNECs indicated a significant concordance of 243 genes between both datasets (read count ≥2, r = 0.6) ([Figure S5](#mmc1){ref-type="supplementary-material"}D). We, therefore, demonstrate that (1) a majority of human fetal PNECs do not express EPCAM and (2) iPNECs have significant gene expression concordance with human fetal PNECs.

iPNECs Express and Secrete Major Neuropeptides {#sec2.6}
----------------------------------------------

PNECs contain vesicles filled with neuropeptides, amines, and neurotransmitters that are secreted upon stimulation. Recently, neuropeptides proenkephalin (PENK), somatostatin (SST), and neurotransmitter synaptic vesicle protein 2 (SV2) have been shown to be secreted by primary PNECs ([@bib4]). Differentiation cultures at days 31, 60, and 91 containing greater than 30% iPNECs ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}) express PENK, SST, and SV2 at the mRNA level ([Figure 5](#fig5){ref-type="fig"}A). ENO2 secretion has been widely used as a biochemical marker to monitor the progression of PNEC-associated disorders, namely SCLC and pulmonary neuroendocrine tumors ([@bib1], [@bib23]). Immunostaining of our cultures at Day 91 confirms that the majority of SYP^+^ cells co-express ENO2 ([Figure S6](#mmc1){ref-type="supplementary-material"}B). We, therefore, proceeded to perform an ELISA to evaluate whether SYP^+^ iPNECs also secrete ENO2. Media were collected from the basolateral compartment of Day 91 ALI cultures used for the scRNA-seq experiment using basal media and iPSC-conditioned media as negative controls and recombinant ENO2 as a positive control. Day 91 differentiation cultures, containing \>30% iPNECs ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}), expressed ENO2 at mRNA ([Figures 3](#fig3){ref-type="fig"}D and [S6](#mmc1){ref-type="supplementary-material"}A) and protein levels ([Figure 5](#fig5){ref-type="fig"}B) in the absence of external stimulation, showing similarity in terms of their gene expression profile to primary PNECs as previously shown ([@bib10]). It is important to note that scRNA-seq analysis indicates that ENO2 expression is only found in the defined iPNEC populations ([Figure S6](#mmc1){ref-type="supplementary-material"}A) supporting selective release of ENO2 from iPNEC in our Day 91 cultures.Figure 5Neuropeptide and Marker Expression Profile of iPNECs(A) qRT-PCR showing the neuropeptide profile of cultures at Day 0, 31, 60, and 91 of differentiation. Data are normalized to internal control β-actin and expressed as comparisons among Days 31, 60, and 91 with respect to Day 0. N = 3 experimental replicates each with 3 technical replicates. One-way ANOVA. ∗p \< 0.05, ∗∗∗∗p \< 0.0001.(B) Enzyme-linked immunosorbent assay (ELISA) data showing secreted levels of enzyme ENO2 in the culture media. N = 4 experimental replicates. One-way ANOVA, ∗∗∗∗p \< 0.0001.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Human Basal Cells Are Capable of Differentiating into PNECs {#sec2.7}
-----------------------------------------------------------

Lineage tracing studies in mice have indicated that TP63^+^ basal cells can give rise to PNECs ([@bib60]). To determine whether human basal cells are also able to differentiate into PNECs, we performed two experiments: (1) pseudotime analysis of our human differentiation Day 91 iPNEC scRNA-seq data and (2) ALI differentiation of purified human tracheal epithelial cells (HTECs). We analyzed the scRNA-seq data of Day 91 differentiation cultures to track cell population changes across the differentiation trajectory ([Figure 4](#fig4){ref-type="fig"}). A stream plot was generated using Stream and Monocle3 for easy visualization of the different cell types in our cultures projected onto the differentiation trajectory "tree" according to their pseudotime locations and the distances from their assigned branches ([Figure 6](#fig6){ref-type="fig"}A). Based on the cell state during the reprograming each cell type/population is assigned to a distinct "branch" of the "tree" representing a specific cell fate choice/developmental lineage that proceeds down a distinct path. Cells on the same or nearby branches are predicted to be hierarchically related. The stream plot ([Figure 6](#fig6){ref-type="fig"}A) indicates that several different cell types are present in our Day 91 differentiation cultures including basal cells, respiratory smooth muscle-like cells, fibroblast-like cells, and iPNECs. We demonstrate that the key genes expressed in the S3 -- S0 branch overlap with the published human lung basal cell database ([GSE24337](ncbi-geo:GSE24337){#intref0025}), confirming that iBasal cells in this culture possess a transcriptomic signature resembling that or primary human basal cells ([Figure 6](#fig6){ref-type="fig"}B). We tracked six key PNEC marker genes, INSM1, UCHL1, NCAM1, SYP, NEUROD1, and ENO2 across the branches where a significant increase in their expression was detected as the cells transition from the iBasal cell state into the two iPNEC trajectories S0 -- S1 or S0 -- S2 (p \< 0.001, [Figures S7](#mmc1){ref-type="supplementary-material"}A--S7F). To further confirm the differentiation of iBasal cells to iPNECs, we used the reverse graph embedding tool in Moncole3 to reconstruct an unbiased lineage trajectory and assigned iBasal cells as the starting cell lineage ([Figure 6](#fig6){ref-type="fig"}C). Cells start at the root (State 1) and progress to one of the two alternative reprogramming outcomes, denoted by State 2 or State 3. Monocole3 trajectories support that iBasal cells differentiate into two states, State 2 and State 3, which correspond to the two different states of iPNECs, iPNEC^1^ and iPNEC^2^ respectively. Therefore, it is possible that the two populations observed in graph-based clustering in [Figure 4](#fig4){ref-type="fig"}A represent two different physiological states of iPNECs, as observed by Monocle3 ([@bib51], [@bib52], [@bib53]). Analysis of the differentially expressed genes between State 2 (iPNEC^1^) and State 3 (iPNEC^2^) indicates a difference in the level of the PNEC marker gene expression. UCHL1, NCAM1, and INSM1 are high in iPNEC^1^, whereas SYP and ENO2 are high in iPNEC^2^ ([Figure 6](#fig6){ref-type="fig"}D). Overall, the pseudotime trajectory analysis supports an iBasal cell predating iPNECs in the differentiation protocol described in this article. Purification and expansion of iPSC-derived basal cells is currently challenging. We therefore used HTECs to corroborate our *in silico* finding. HTECs, consisting almost exclusively of a self-renewing population of KRT5^+^/TP63^+^ basal cells ([Figure S8](#mmc1){ref-type="supplementary-material"}A), were cultured at the ALI and stained for SYP. After more than 75 days of differentiation at the ALI, the distribution of SYP staining in the cultures was estimated to be 17.71% ± 2.49% based on the relative MFI percentage of SYP:DAPI ([Figures 6](#fig6){ref-type="fig"}E, 6F, and [S8](#mmc1){ref-type="supplementary-material"}B). Using two independent approaches our data strongly suggest that human basal cells, both iPSC-derived and primary, are capable of giving rise to PNECs.Figure 6Human Basal Cells Differentiate into PNECs(A) Stream plot of scRNA-seq data showing lineage differentiation trajectories of iPSC-derived Day 91 cultures. Cells are assigned a distinct color based on cell types. Cells on the same branch are predicted to be hierarchically related.(B) *Z-*score of highly enriched genes across S3 -- S0 trajectory that overlaps with human lung basal cell microarray dataset GSE24337). Relative gene expression level across each trajectory was calculated as a *Z-*score of log2 (CPM+1) where CPM denotes counts per million. A positive *Z-*score indicates a score that is higher than the mean.(C) Monocle-based lineage reconstruction of pseudotemporal trajectories superimposing both cell fate and cell states during differentiation from iBasal cells to iPNECs. Cells can differentiate from State1 (iBasal cells) to State 2 (iPNEC^1^) or State 3 (iPNEC^2^).(D) *Z* score of highly enriched genes across trajectories S0 -- S1 and S0 -- S2 corresponding to two states of iPNECs, iPNEC^1^ and iPNEC^2^ respectively.(E) Representative immunofluorescence images showing SYP^+^ PNECs (red) in \>78 days ALI cultures from primary HTEC. Scale bars, 25 μm.(F) Quantification of SYP^+^ PNECs in HTEC cultures expressed as MFI percentage of SYP fluorescence relative to total DAPI fluorescence.Data are expressed as mean ± SEM. N = 7 experimental replicates. See also [Figures S7](#mmc1){ref-type="supplementary-material"} and [S8](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

We have established a directed differentiation strategy for deriving iPNECs from human iPSCs that are transcriptomically similar to human fetal primary PNECs. Generation of these cells from a renewable and patient-specific cellular source overcomes limitations with regard to accessibility to sufficient primary human PNECs and enhances our capacity to model human diseases, like NEHI. Recent reports have demonstrated the generation of PNEC-like cells from human pluripotent stem cells; these studies, however, focused primarily on their sporadic presence in spheroid cultures or on their potential as lung cancer models ([@bib6], [@bib25]) (*17*, *18*). To date, there has been no in-depth phenotypic and transcriptional characterization of these cells to validate their similarity to their primary counterparts. The iPNEC differentiation protocol described in this article is adapted from our previously established airway epithelial differentiation protocol to specifically promote differentiation toward the neuroendocrine lineage ([@bib13]). Using this model we are able to generate iPNECs expressing all major PNEC marker genes including *SYP, CHGA, PGP9.5, ROBO2,* and *ENO2*, consistent with primary human and rodent PNECs ([@bib4], [@bib30], [@bib49]). By specifically adapting the culture conditions to favor expansion of PNECs we are able to generate cultures with an increased efficiency of generating iPNECs over currently published protocols ([@bib6]). Our differentiation is robust across multiple iPSC lines despite inherent variability between stem cells lines/clones with regard to their differentiation efficiency. Furthermore, differentiation protocols, such as those developed in this study, rely on the sequential application of growth factors and cytokines directing differentiation toward lung epithelium: at any given point cells may be captured at varied stages of differentiation and maturation, again contributing to heterogeneity. It should be noted that our iPNEC protocol does not utilize any purification steps and thus an endpoint culture composed of mesenchymal (niche) cells and epithelium is generated with the iPNECs. Isolation of iPSC-derived lung basal cells, akin to primary HTEC, and differentiation toward PNECs may reduce this variability; however, loss of putative niche cells may also impact efficiency. Such factors will be evaluated in a subsequent study (Ryan laboratory, unpublished data).

Interestingly, we found that exposure to an air interface was important for the continued development of iPNECs. This condition typically mimics the microenvironment of the postnatal and adult lung ([@bib54], [@bib58], [@bib57], [@bib59]). This observation has not previously been reported, and although PNECs first appear in the embryonic lung when the lung is filled with amniotic fluid ([@bib20], [@bib34]), it is in the adult lung, when the lung is exposed to air/oxygen, that PNECs are known to function as airway chemosensors ([@bib14], [@bib30], [@bib36], [@bib49]). Our protocol mimics this trajectory, with iPNECs being detected for the first time around Day 13 of differentiation, correlating with the early specification of NKX2.1-expressing anterior foregut endoderm cells ([Figure S1](#mmc1){ref-type="supplementary-material"}B); at this stage the cultures are still submerged. Persistent culture in submerged growth conditions after specification of the primordial lung progenitor results in complete loss of the SYP-expressing cells suggesting that this microenvironment is not conducive to their continued growth and proliferation. There are a number of factors that may influence this including exposure to a more hypoxic environment upregulating hypoxia response genes such as HIF-1α and HIF-2α causing an upregulation of Notch signaling, as previously reported ([@bib16]). Notch upregulation, in turn, is known to be antagonistic toward PNEC fate induction ([@bib61]). Existing literature has not specifically indicated a requirement for an ALI during differentiation to generate PNEC-like cells ([@bib6], [@bib25]). Other iPSC-derived PNECs have been generated in submerged cultures by formation of spheroids/organoids perhaps accounting for differences in iPNEC yield observed between these protocols and our current protocol. The continued and strong suppression of Notch signaling favors PNEC specification in our protocol. We did not observe significant numbers of ciliated cells under these conditions in contrast to our original protocol. We speculate that this may be due to continuous and increased (10-fold higher) levels of Notch suppression. These cultures were observed for over 3 months, and a substantial increase in both the number and the phenotypic complexity of iPNECs was evident. Although it is currently not possible to determine the precise maturity of iPNECs due to a lack of adult human isolated PNECs for direct comparison, our data suggest that the increase in branched network formation in iPNECs may correlate with their cellular maturation over time.

PNECs are considered neuroepithelial in nature ([@bib9], [@bib55]) as they arise from the undifferentiated epithelial progenitors located at the Id2^+^ (inhibitor of DNA binding 2) distal tips of the branching epithelium along with all other epithelial cell lineages within the lung ([@bib42], [@bib47]). However, neither primary nor induced SYP^+^ PNECs were observed to co-express the epithelial marker, EPCAM. This finding is in contrast to a recent study in mouse ([@bib33]), where analysis of scRNA-seq on purified EPCAM^+^ tracheal epithelial cells identified a specific cell cluster as neuroendocrine. It should be noted that no analysis of EPCAM-negative cells was performed. There are also no published studies that show co-staining of human PNECs with EPCAM. Furthermore, we found that 65% of human fetal PNECs analyzed in the dataset from Miller et al. is EPCAM^−^ and shows a high level of gene expression concordance with our iPNECs ([@bib32]). Interestingly, we did not observe CGRP expression in our iPNECs. CGRP is often used as a PNEC marker; however, its expression and distribution in PNECs appears to vary among species. CGRP expression in humans, for example, has been observed to correlate to a cancer phenotype ([@bib12]) and observed to only be present in ∼20% of primary lung PNECs ([@bib56]). In human lungs, bombesin/GRP is more robust and widely accepted as a marker of fetal-stage PNECs ([@bib30], [@bib49], [@bib50]). Consistent with the literature, we also observe GRP expression peaking during the earlier stages of iPNEC differentiation (Days 13 and 17).

Primary PNECs are known to contain neuropeptides that are stored in dense core vesicles in the cytoplasm and are secreted in response to external stimuli such as hypoxia, nicotine, or tobacco smoke ([@bib4], [@bib9], [@bib30]). The iPNECs generated in this study exhibit similar secretion of ENO2 and expression of neuropeptides. ROBO genes that help form sensory organoid clusters *in vivo* via a Slit-ligand-dependent process are also a known feature of mouse PNECs ([@bib4]).

Due to a lack of gene expression data focusing on PNECs only a small list of genes is available to define and study PNEC. We hypothesize that our 255 iPNEC-associated genes could serve as a more comprehensive gene set for PNECs and acknowledge that it will be important to validate the iPNEC-associated gene signature in adult human PNECs. Interestingly, our scRNA-seq data indicated two distinct iPNEC clusters from both the t-distributed Stochastic Neighbor Embedding (tSNE) and stream plot analyses, with additional analysis of cell trajectory predicting that the two clusters correspond to two individual physiological states. In a recent publication, rare Notch2^+^ NE^stem^ and intermediate transit amplifying Hes1^+^ Notch-active NE cells that contribute to epithelial repair during lung injury in mice were identified ([@bib38]). Despite maintaining our 90-day iPSC PNEC differentiation in the continued presence of Notch inhibition we are able to observe two individual iPNEC populations with differential levels of Notch2 and Hes1 expression. We hypothesize that these two distinct subpopulations, iPNEC1^1^ (low Notch) and iPNEC^2^ (high Notch), may resemble the PNEC heterogeneity observed by Ouadah and colleagues ([@bib38]); however, this will require further validation and development of a similar injury model using human iPSC-derived PNECs.

In conclusion, we have successfully derived PNECs from human iPSCs that resemble the known phenotype of human fetal and adult primary PNECs at the cellular and molecular levels. This represents an important step toward creating human cellular models for investigation of lung diseases characterized by PNEC hyperplasia, such as NEHI.

Limitations of the Study {#sec3.1}
------------------------

In this study, we undertook the directed differentiation of human iPSCs into PNECs and performed robust characterization of these iPNECs at the cellular and molecular levels. Although we were able to demonstrate significant gene expression concordance with human fetal lung PNECs, it will be important to also make comparisons to the transcriptomes of human adult lung PNECs as these data become available to determine the maturation state of our iPNECs. With \<1% of the cellular composition of the adult lung being PNECs, it remains challenging to capture sufficient cells to profile. Currently, methods for the specific isolation/enrichment of PNECs do not exist, making such comparisons extremely challenging. Although we have included experiments that support a functional profile for the iPNECs such as the expression and secretion of major neuropeptides ([Figure 5](#fig5){ref-type="fig"}), additional experiments will be important to further establish their functional competency. Such experiments might include measurement of neuropeptide release under hypoxic conditions and mechanical stress or in response to allergic stimulants, which would also be beneficial for disease modeling. Although analysis of our scRNA-seq datasets indicates the presence of two PNEC populations, in the current article the functional differences between these two populations were not addressed. In future experiments it would be interesting to determine whether these are two independent PNEC populations or whether they are cells at different stages along the differentiation trajectory. It also remains unclear whether primary or induced PNECs can be expanded *ex vivo*. This would require an extensive series of experiments to optimize both the purification and culture of both PNEC and iPNECs; however, this would be incredibly valuable to further study the biology of PNECs. Finally, to definitively confirm a basal cell origin of PNECs, lineage tracing will need to be performed in both primary HTECs and iPSC-derived cultures requiring the generation of iPSC reporter lines.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

We have uploaded and made available our single-cell RNA sequencing data generated from our Day 91 differentiation cultures on Gene Expression Omnibus (GEO) database under accession number: [GSE146990](ncbi-geo:GSE146990){#intref0030}.
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